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Change in alkaline phosphatase isoenzyme pattern in urine as
possible marker of renal disease. The human kidney contains two
types of alkaline phosphatase (AP) isoenzymes: a hepatic type of
AP and an intestinal-like AP. Intestinal-like AP, measured by
immunotitration techniques, is a minor component (I to 4%) of
the total AP activity. It is found only in the particle-free fraction
(cytoplasm) and is located, with immunofluorescent tech-
niques, in some of the proximal convoluted tubules. Urinary AP
activity is found after high-speed centrifugation in the super-
natant (x IOO,000g). as well as in the sediment, and may be ex-
tracted from the sediment after solubilization with n-butanol.
Both types of these renal isoenzymes contribute to urinary AP
activity. Biochemical characterization (effect of inhibitors, ther-
mostability. denaturing with urea, and so on) revealed that uri-
nary intestinal-like AP and renal intestinal-like AP are identical.
Both, however, have been distinguished as multiple forms of AP
from the small intestine. Most of the urinary AP activity of
healthy persons (22 volunteers) was found in the sediment and
consisted of liver-type AP. Urinary AP of patients with diseases,
after application of potentially nephrotoxic drugs or during re-
jection episodes of renal allografts. contains little sediment activ-
ity, but it contains increased amounts of urinary intestinal-like
AP.
Modification de I'aspect des isoenzymes de Ia phosphatase alka-
line (AP) dans l'urine comme marqueur possible d'une affection
rénale. Le rein humain contient deux types d'isoenzymes de
l'AP: le type hepatique et un type semblable a l'enzyme in-
testinale. L'AP intestinale déterminé par immunotitration, est un
composant mineur (I a 4%) de l'activité totale de AP. L'AP in-
testinale est trouvé seulement dans Ia fraction cytoplasmique et
localisé dans quelques convolutions proximales comme Ic
montre l'immunofluorescence. L'activité AP de l'urine est ob-
servée aprés centrifugation a grande vitesse dans le surnageant
>< lOO,000g de méme que dans le sediment et peut être extraite du
sediment par solubilisation dans le n-butanol. Les deux types
d'isoenzymes observes dans le rein contribuent a l'activité AP
de l'urine. La caractérisation biochimique (effet des inhibiteurs,
thermostabilité. dénaturation par l'urlée, etc.) révéle que l'AP
intestinale de I'urine et lAP intestinale de le rein sont identiques.
Cependant, ces deux formes ont ëté reconnues comme des
formes multiples de lAP intestinale isolée de l'intestin gréle. La
plus grande partie de l'activité urinaire de lAP chez des sujets
sains (22 volontaires) a été découverte dans Ic sediment et con-
sistait en AP de type hepatique. L'AP urinaire de malades, apres
administration de drogues nephrotoxiques, au cours d'épisodes
aigus de rejet, contenait peu d'activité sédimentable mais des
quantités élevées de lAP intestinale urinaire.
Previous investigations [1—3] presented evidence
that the mammalian and human kidney contains two
antigenically distinct isoenzymes of alkaline phos-
phatase (AP): one is a liver type (KL) and the other
an intestinal type (K1). Alkaline phosphatase activi-
ty (orthophosphoric monoester phosphoh ydrolase
[alkaline optimum], E.C. 3.1.3.1) in rat kidney tis-
sue was localized in the microvilli of the proximal
tubules [4]. So far, the differentiation of these isoen-
zymes has not been made in the kidney regarding
their ultrastructural localization and biochemical
function.
Butterworth et a! [5] and recently Korngold [6]
described the urinary AP as having a lower molecu-
lar weight compared with kidney AP and as reacting
with an intestinal AP antiserum. But because their
studies were concentrated primarily on urinary AP
of patients with proteinurea or acute tubular necro-
sis, no comparison to the urinary form of healthy
persons could be drawn.
Because the immunotitration technique was
found to be a suitable tool for investigating the
isoenzyme pattern of various enzymes in blood or
tissue [7, 8], we used this method to study the alka-
line phosphatase isoenzymes of kidney and urine so
that we could compare the output of these various
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isoenzymes under normal and pathologic condi-
tions. Furthermore, we extended our investigations
to the influence of the aminoglycosides on the AP
isoenzyme pattern in kidney and urine. The nephro-
toxicity of aminoglycosides is a known fact [9-11],
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and the determination of the daily output of mem-
brane-bound enzymes, such as alanine amino-
peptidase, as a more sensitive indicator of the renal
damage, has reconfirmed this.
Methods
Enzyme assay. Alkaline phosphatase activity was
measured, by the method of Hausamen et a! [12], at
25° C with 10 mr'i p-nitrophenylphosphate as the
substrate in I M diethanolamine and hydrochloric
acid buffer (pH, 9.8) in a final volume of I ml, con-
taining 0.5 m magnesium chloride. Enzyme sam-
ples were preincubated for at least 15 mm in the test
buffer. The reaction was started by adding the sub-
strate. Absorbance change was measured at 405 nm
in an Eppendorf photometer (e = 18.2 cm2/imo1e).
Creatine kinase was tested by the N-acetylcysteine-
activated method of Oliver [13]; lactate dehy-
drogenase activities, by the standard method; and
alanine aminopeptidase, by a previously described
method [14]. Enzyme activities are given as inter-
national units.
Preparation of antibodies. Rabbit antisera
against purified AP isolated from calf intestinal mu-
cosa and human kidney were produced by the meth-
od described recently [2]. They were purified on
protein A [15] without significant loss of immuno-
logic activity, as already described [14].
Cell fractionation was done in 0.25 M sucrose by
differential centrifugation, as described by Schneid-
er [16]. The cytoplasmatic fraction (x 18,000g) had
been further purified from membranous particles by
ultracentrifugation (X 100,000g, 60 mm).
Butanol extraction of membrane-bound AP activ-
ity in urine and tissue homogenates was done with
a threefold amount of 30% n-butanol and 70% Tris
hydrochloric acid(lO mM; pH, 7.5)containing2 mM
magnesium chloride and 0.025 m zinc chloride
(standard buffer). Tissues were homogenated with a
Potter-Elvehjem. The mixture was allowed to stand
first at room temperature for 12 hours; afterwards
it stood in the cold for 12 hours, continuously being
stirred. After centrifugation, the solution was di-
alyzed against standard buffer.
1,nmunotitration assay. For our routine precipi-
tation test, we usually incubated 10 mU of AP in a
standard buffer solution containing 2.5%polyethyl-
ene glykol and 0.2% of bovine serum albumin with
increasing amounts of antiserum either against kid-
ney AP or intestine AP in a total volume of 200 l.
Addition of bovine serum albumin has been found
suitable to stabilize enzymatic activity under pres-
ent conditions. The incubation mixture was in-
cubated for 1 hour at 37° C, and afterwards it was
kept in the cold overnight. After it was centrifuged
at high speed (30 mm, x48,000g), we estimated the
difference between the residual activity in the su-
pernatant and the blank without antiserum. The dif-
ference revealed the actual amount of the various
isoenzymes. Knowing the titers of our applied anti-
sera and for simplifying this method, we just deter-
mined the final point of the titration curve by in-
cubating the assay with an excess of antiserum. One
complication occurred when we compared the im-
munotitration technique for either human tissue ex-
tract with that for AP in urine. We needed more
antiserum, in the case of urine AP, to get the quan-
titative precipitation. Urine samples were concen-
trated up to /25 of the initial volume and ultracentri-
fuged (x 100,000g, 60 mm).
Separation of AP isoenzymes by affinity chro,na-
tography. Ultracentrifuged tissue homogenates and
urinary samples were dialyzed against 10 mt Tns
hydrochloric acid (pH, 8.0). Affinity chromatogra-
phy on L-histidyl-diazobenzylphosphonic acid aga-
rose was carried out as described by Landt, Boltz,
and Butler [17]. The eluted enzymes were tested by
immunotitration for their antigenetic purity.
Electrophoresis on cellulose acetate stripes was
carried out in Boskamp chambers, with 48 mi Tris
barbituric acid (pH, 8.6). With a voltage of 200 V,
electrophoresis was carried out for 2 hours. Enzy-
matic staining of AP was performed with a-naph-
thylphosphate [2] as substrate and with Fast blue
BB salt as the coupling dye component, as de-
scribed [18].
Molecular weight was determined with a Beck-
man ultracentrifuge and polymer tubes that con-
tained 4 ml of standard buffer. Sucrose gradient
was obtained by the overlaying of 0.5 ml of 20%
sucrose-Tris buffer solution by 0.5-mi portions with
decreasing contents of sucrose up to a final concen-
tration of 5% sucrose. The gradient was allowed to
develop by standing for 4 to 6 hours. The sample
was applied together with creatine kinase, lactate
dehydrogenase, and hemoglobin above the gradient
solution in a volume of 20 to 50 l by an Eppendorf
pipette. The centrifuge was run for 20 hours. All
tubes were eluted by fractioning into 23 fractions.
Creatine kinase and lactate dehydrogenase activi-
ties were tested, and the distance of hemoglobin
from the start was measured. Molecular weights
were determined by the equations of Martin [20].
Molecular weight by gel filtration was determined
with a Sephacryl S-200 superfine column (140 x 1.5
cm) in buffer, containing 0.2 M sodium chloride to
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avoid any ionic interaction. Lactate dehydro-
genase, creatine kinase, and bovine serum albumin
were used as standards; void volume was deter-
mined by Dextran-blue.
Inhibition studies were carried out by incubating
the enzyme with i-phenyl-alanine for 15 mm in a
usual test buffer [20]. Heat stability was tested by
incubating the enzyme diluted in standard buffer for
90 mm at 56° C, cooling it immediately afterwards,
testing it as usual, and comparing it with the same
enzyme dilution that was not heated before and
tested in the same way.
Inactivation test in 5 M urea was carried out in the
test buffer by incubating the sample for 90 mm. An
aliquot was incubated for the same time in the test
buffer without urea and was taken to have 100% re-
sidual activity.
Immunofluorescence. For localizing the intestinal
AP isoenzyme in the human renal tissue, we used 7-
m thick cryostat sections from nitrogen-frozen
blocks of fresh, normal, cadaveric kidney. In the
two-layer (indirect) staining method, the unfixed
sections were incubated for 20 mm at 37° C in a
damp chamber with serial dilutions of the rabbit
antiserum (as IgG) against intestinal AP isoenzyme.
The incubation was followed by three-fold careful
washing in PBS and a second incubation under the
same conditions with 1:8 diluted FITC-labeled anti-
rabbit goat antiserum (Miles). The washed sections
were examined under a Universal Microscope Zeiss
with a mercury vapour burner and a cardioid con-
densor. The exciting filter used was BG 12/3 (green
exciting), and the barrier filter was GG9. The same
sections, incubated with only FITC-labeled anti-
rabbit antiserum, others with rabbit antiserum anti-
intestinal AP by itself, were used as controls. The
controls showed no fluorescent staining.
Results
Distribution of AP isoenzymes in urine. Ultra-
centrifugation of urine samples of healthy persons
revealed that only about 35% of total AP activity is
found in the particle-free fraction (x lOO,000g super-
natant) (Table I). The relative amount of soluble AP
increased in a significant way in the urine of patients
with renal disease, such as pyelonephritis or gb-
merulonephritis, and alter kidney transplantation,
but also in the urine of healthy persons after amino-
glycosides-treatment. Comparing the daily output
of AP of such pathologic urine with that in normal
urine, it was obvious that this change in the relative
amount of sedimentable AP activity was not due to
an increase of enzymatic activity.
While investigating AP isoenzyme patterns in
urine by immunotitration technique, we found two
isoenzymes present in urine: a "liver-like" fraction
(UL) and an "intestinal-like" one (U1). The AP ac-
tivity of the sediment obtained by ultracentrifuga-
tion consisted of approximately 90% and more of
UL. Only in a few samples, small amounts of up to
10% of U1 were found.
The urinary AP activity found in the supernatant
contained intestinal AP in an amount of about 50%
for healthy persons and of 70 to 80% for patients
Table I. Distribution of alkaline phosphatase (AP) isoenzymes in human urine°
.
Diagnosis
AP
U/liter
AP
in U/24 hr
.AP in particle-free
fraction
--.---______
% m U/24 hr
Lsoenzyme pat
——
tern of total AP5
——
U1
______
%
UL
in U/24 hr% m U/24 hr
Control (22
individuals) 3.5 5829 35 2040 19 1108 71 4139
Range (2.2to5.6)
5.6)
(3950to7980) (13to53) (416to2892) (9to29) (589to 1518) (47to80) (2447to5l58)
ChronicGN 3.8
2.1
6878
683
46 3168
78 532
15
64
1045
436
83
36
5706
243
GN 5.7
5.0
5244
5082
56 2937
90 4574
26
69
1380
3506
65
10
3423
508
PostGN 2.4 1632 54 881 14 231 78 1273
Chronic PN 3.4
1.5
6.8
8432
1680
11696
71 5987
77 1294
74 8655
66
59
52
5574
996
6128
33
41
45
2790
684
5276
Nephrotic syndrome 2.8
8.7
10416
6160
61 6353
87 5359
50
47
5216
2880
53
58
5557
3572
Suspicion of
hydronephrosis 4.6 8004 48 3842 39 3130 63 5036
Renal insufficiency 3.5 5460 88 4805 61 3324 37 2040
a Abbreviations are defined as: GN. glomerulonephritis; PN, pyelonephritis; U1, intestine-like AP in urine and: UL, liver-like AP in
urine.
11 Determined by immunotitration.
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Fig. 1 a to c. Mean urinary level of alkaline phosphatase (AP),
alanine aminopeptidase (AAP) activity, and isoenzyme pattern
of AP before, during, and after i.m, administration of gen-
tamicin (3 mg/kg) and cefazedon (6 g) on 3 consecutive days.
with renal disease. The rest of the AP activity was
attributed to the liver-like isoenzyme. Based on the
change of solubility, therefore, the total urinary AP
from healthy persons contained about 19% intesti-
nal-like isoenzyme (U1), whereas in the urine from
patients with renal disease this form increased to
about 50 to 60% of the total activity (Table 1).
The application of a combination of cefazedon
and gentamicin to healthy persons caused a nearly
fivefold increase of AP activity in the urine, parallel
to an increase of soluble enzyme up to 80 to 90%
from day 2 after the first application, with a maxi-
mum of 2 days or even later after the end of the
application. The isoenzyme pattern changed in such
a way that U rose after application while UL re-
mained nearly constant (Fig. I, a to c). Series of
urine samples of one person after kidney trans-
plantation were tested for AP activity, sedimenta-
tion property, and isoenzyme pattern. We found a
fourfold increase of urinary AP activity. The maxi-
mum was reached on day 11 after the transplan-
tation due to an increse of U1 in urine, going up
from approximately 3000 mU/24 hours immediately
after transplantation to 27,000 mU/24 hours on day
11. Alanine aminopeptidase, which is regarded as a
sign of rejection crisis, reached its maximum on day
9 (Fig. 2).
Amount and localization of K1 in human and bo-
vine kidney. So far, human kidneys investigated for
AP isoenzyme pattern exhibited the presence of I to
4% K1 ("intestinal-like") of the total activity besides
the KL ("liver-like") AP. Cell fractionation studies
were carried out with bovine kidney, which con-
tains the same amount of intestinal-like AP as does
the human kidney, by the differential centrifugation
method of Schneider [16]. They were resected im-
mediately after death and used for experiment on
the same day without freezing. These conditions
were necessary to avoid cellular destruction and
could not be fulfilled by human tissue. These exper-
iments revealed that K1 is located only in the cyto-
sol (Table 2). No membrane-bound K1 was found.
When the tissue of the human kidney was cut into
five sections, from the surface to the interior of the
organ, K1 was found in the cortex (Fig. 3), whereas
no K1 was located in the medulla. To obtain further
information about the morphologic origin of K1, we
carried out immunofluorescence studies on human
kidney with purified antiintestinal AP serum. The
renal cortex showed fluorescence in about 10% of
all observed convoluted tubules. No staining was
remarked in the glomeruli and medulla (Fig. 4).
Biochemical characterization of intestinal-type
AP (human) isolated from intestine, kidney (K1),
and urine (U1). Homogenates of intestinal and kid-
ney tissues, as well as of urine, usually contain both
isoenzymes of AP, liver-type and intestinal-type, in
various amounts. To achieve enriched isoenzyme
preparations, we carried out affinity chromatogra-
phy with L-histidyldiazobenzyl phosphonic acid
a Subject I (female, 23 years old, 59 kg body wt)
Gentamicin + cefazedon333
Time, days
b Subject 2 (female, 31 years old, 59kg body wt)
Gentamicin + cefazedon
C
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agarose 11171. As Mössner and Pfleiderer have found
(unpublished results), only intestinal-like AP (free
of neuraminic acid) was bound by means of this
technique. Therefore, it was possible to separate K1
completely from KL. About I U of each form had
been prepared from crude kidney extract or urine.
As proven by immunotitration technique, none of
these fractions contained even a small amount of
the liver-like isoenzyme.
Immunologic studies could demonstrate that K1
and U1 antigens are precipitated, as well as in-
testinal AP, by using anticalf intestinal AP serum as
antibody. No remarkable difference in its titer
against these antigens could be detected. Although
affinity of antibodies used in these experiments was
different against human and bovine antigens, they
showed good cross-reactivity. So they could be
used in the experiments described above. Determi-
Table 2. Cellular distribution of alkaline phosphatase (AP) in
bovine kidney, estimated by means of fractionated centrifugation
lsoenzyme
Fraction
.
APactivity
% of total aetii'itv
patterns,
--
K1. K1
Nuclear 8 100 0
Mitochondrial 12 100 0
Microsomal 53 100 0
Plasma membrane 20 100 0
Cytoplasm 7 80 20
K1 is liver-like AP in kidney; K1 is intestine-like AP in kid-
ney.
nation of the molecular weight with ultracentrifuga-
tion in sucrose density gradient exhibited 124,000
daltons for all three forms. These findings were in
contrast to results achieved by gel filtration experi-
ments on a Sephacryl S-200 superfine column, in-
dicating a lower molecular weight of 80,000 daltons
for U1, compared with 120,000 to 130,000 daltons
for intestinal AP found by using the same tech-
nique.
Other parameters used for differentiating AP
isoenzymes revealed that intestinal AP and K1 or U1
represent multiple forms of the same isoenzyme.
Table 3 shows greater heat stability of both K1 and
U1. K1 showed 45 to 60% and U1 showed 51 to 60%
residual activity in contrast to 10 to 25% residual
activity of intestinal AP after heating for 90 mm up
to 560 C. After incubation for 90 mm in 5 m urea,
15% for K1, 18% for U1, and 40% residual activity
for intestinal AP were found.
K1 and U1 were less inhibited by 5 ms'i t-phenylal-
anine (K1: 43 to 84%, U1: 60 to 70%) than was the
intestinal AP (16 to 23% residual activity). No dif-
ference in their electrophoretic migration behavior
could be detected when applied to cellulose acetate
stripes. To establish whether these differences were
caused by butanol extraction, we compared the
butanol-extracted intestinal enzyme with that of
)< 100,000g supernatant of intestinal homogenate.
Both intestinal forms could not be differentiated.
We also could not find any difference between U1
isolated from the urine of healthy persons, renal pa-
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Fig. 2. Mean urinary level of alkaline phospliatase (AP), alanine am inopeptid,se (AAP) aCtil'itV, and AP isoen:yme pattern after kidney
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"intestinal-like" AP isoenzyme
1% of AP activity)
I
6
Medulla Cortex
Fig. 3. Distribution of intestinal-like alkaline phosphatase (AP)
isoenzwne K1 in human kidney.
tients, and subjects undergoing aminoglycoside
treatment.
Discussion
By means of an immunotitration technique, the
isoenzyme pattern of alkaline phosphatase in the
urine of healthy persons has been differentiated
quantitatively from that of patients with renal dis-
eases or under application of potentially nephrotox-
ic drugs. The amount of particle-free AP cone-
lates with the increase of the U1 AP during patho-
logic renal processes. The elution of sedimentable
activity apparently can be correlated with the
excretion of renal cell fragments, mainly in urine. In
electronic microscopic studies, it could be demon-
strated that urine contains microvilli of cell mem-
branes (as complete or vesicle-degenerated micro-
villi).
Apparently the two AP isoenzymes, the liver (K1)
and the intestinal (K1) types, extracted from kidney
tissue are associated with distinct sites on the tubu-
lar epithelia and may represent different develop-
mental stages of the epithelial cells of the proximal
convoluted tubules. It has yet to be discussed
whether K1 belongs to earlier developmental stages
of the proximal tubule. As shown by immuno-
fluorescent microscopy, K1 is located only in single
parts of the proximal tubules in the normal renal
cortex.
Biochemical characterization of the three in-
testinal types (intestinal AP, K1 and U1) evidenced
that K1 and U1 can be distinguished as multiple
forms of the intestinal AP isoenzyme. The reason
for the differences between the K1 and the intestinal
Fig. 4. Human kidney, i,n,nunofluorescent staining of intestinal-like alkaline phosphatase, K, ( XIOO).
10%//i
Segments
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Table 3. Properties of intestinal alkaline phosphatase (AP) isoenzyme isolated from intestine (I),
kidney (K1), and urine (U1) of human tissue
Molecular
Sample"
Intracellular
localization Km X l0-3M
weight"
do/tons
L-Phe inhibition
%
Heatd
%
Urea"
%
I membrane-bound 0.2 124,000 16 to 23 10 to 25 42
K, cytoplasmatic 0.5 124,000 43 to 89 45 to 60 1518U, particle-free 0.4 124,000 60 to 70 51 to 60
"Isolated by affinity chromatography
b Determined by sucrose density gradient ultracentrifugation
Residual activity after incubation in 5 mi L-Phe for 90 mm
d Incubation at 56" C for 90 mm, residual activity
Incubation in 5 M urea for 90 mm, residual activity
AP could be a different carbohydrate content. The
distinct behavior on the gel filtration experiments
that indicated lower molecular weights for U1 is
probably caused by differences in the shape of the
molecules. Apparently U, only originates from the
kidney because when isolated from urine in all ex-
amined different pathologic states, it exhibited the
same properties as K1.
Previous studies have shown that the AP has to
be described as an intrinsic constituent of the lumi-
nal plasma membrane in the proximal tubule of the
normal human kidney [21, 22]. As alanine amino-
peptidase, which is considered as a superficial com-
ponent of the luminal plasma membrane [23},
reached its maximum of output after administration
of aminoglycosides earlier than did U1, elevation of
U1 activity indicates probably further tubular dam-
age. During kidney rejection crisis after transplanta-
tion the same isoenzyme pattern of urinary AP re-
flects similar renal damage as that caused by amino-
glycosides.
It is likely that under pathologic conditions, more
tubular regions containing U1 are developed. As
these tubules seem to be damaged more, higher per-
meability of cellular proteins through the cell mem-
branes leads to an elevated elution of the intestinal-
type AP (U1) in urine. Therefore, intestinal AP
isoenzyme, which is the reason for increased AP ac-
tivity in urine, seems to indicate a lesion of the
proximal convoluted tubule and/or of an intensive
regeneration of the tubular epithelial cells. An in-
tensive regeneration of these cells occurs certainly
in the recovery phase of renal disease and probably
accompanies a light or medium renal injury. In all
these cases, the increase of the AP in urine appears
to be a consequence of an induction of the synthesis
as a result of a toxic or inflammatory aggression of
the kidney and not only as a result of the loss of the
enzyme from the damaged cells.
In preliminary investigations we could exclude
that the urinary intestinal AP is leaking from the
plasma. During and after application of cytotoxic
substances, an increase of serum AP was never ob-
served, and cytoplasmic "intestinal" like AP could
never be detected.
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